GU Cancer

Checkpoint inhibition option for bladder cancer patients

The TGA has extended use of pembrolizumab (Keytruda) to include locally advanced or metastatic urothelial cancer in patients either not eligible for cisplatin-containing therapies or those who have previously received platinum-containing chemotherapy. As reported previously in the limbic here, KEYNOTE-045 found an overall survival benefit in patients treated with pembrolizumab compared to second line chemotherapy ...

Already a member?

Login to keep reading.

© 2022 the limbic